Kimberly-Clark Corporation (KMB)
| Market Cap | 34.66B |
| Revenue (ttm) | 19.72B |
| Net Income (ttm) | 1.97B |
| Shares Out | 331.86M |
| EPS (ttm) | 5.91 |
| PE Ratio | 17.66 |
| Forward PE | 13.55 |
| Dividend | $5.04 (4.84%) |
| Ex-Dividend Date | Sep 5, 2025 |
| Volume | 5,324,153 |
| Open | 105.02 |
| Previous Close | 104.12 |
| Day's Range | 104.30 - 105.70 |
| 52-Week Range | 99.22 - 150.45 |
| Beta | 0.25 |
| Analysts | Hold |
| Price Target | 129.58 (+24.06%) |
| Earnings Date | Oct 30, 2025 |
About KMB
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates through three segments: North America, International Personal Care, and International Family Care and Professional. The company North America segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers, and other related produc... [Read more]
Financial Performance
In 2024, Kimberly-Clark's revenue was $20.06 billion, a decrease of -1.83% compared to the previous year's $20.43 billion. Earnings were $2.55 billion, an increase of 44.27%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for KMB stock is "Hold." The 12-month stock price target is $129.58, which is an increase of 24.06% from the latest price.
News
Final Trades: Kimberly-Clark, Thermo Fisher, Wabtec and Berkshire Hathaway
The Investment Committee give you their top stocks to watch for the second half.
Jim Cramer calls the bottom in P&G and Kimberly-Clark stock
Famed investor Jim Cramer is sounding the alarm – not of danger, but of opportunity. In a recent segment, the veteran market commentator urged investors to reconsider beaten-down packaged goods stocks...
You've come to expect pain from stocks like Kimberly Clark, says Jim Cramer
'Mad Money' host Jim Cramer talks how to prevent FOMO in investing.
I'm Buying Dividend Aristocrats At Bargain Basement Prices
It pays to buy high quality at a discount. In this article, I highlight two attractively valued Dividend Aristocrats. Both are trading well below their normal valuations and carry historically high di...
A Look at Earnings for Two Stocks
This issue will look a little different. It will read more like the weekly updates I send to my premium Yield Shark readers.
Watch These Stocks Falling 10% Or More
Fiserv (FI) leads decliners with a 49% drop, driven by leadership turmoil, weak consumer spending, and a downgraded quant rating to 'Strong Sell.' Alexandria Real Estate (ARE) and Robert Half (RHI) su...
Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue
Consumer staples ETFs, usually the quiet corner of the market, are suddenly in the spotlight. The $48.7 billion acquisition of Kenvue Inc. (NYSE:KVUE) by Kimberly-Clark Corp (NASDAQ:KMB) has stirred r...
3 Dividend Stocks for November 2025
This month's trio includes two ADRs.
The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker
Mike Hsu aims to stoke the consumer company's growth by veering into Kenvue's higher-margin but risky health products.
Kimberly-Clark CEO Mike Hsu goes one-on-one with Jim Cramer
Kimberly-Clark Chairman and CEO Mike Hsu joins 'Mad Money' host Jim Cramer to talk the recent acquisition of Kenvue, quarterly results, consumer trends, and more.
Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'
Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump ...
Kenvue's legal risks loom over planned acquisition by Kimberly-Clark
Kimberly-Clark said on Monday it plans to acquire Band-Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising qu...
S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue
A linkup with an artificial intelligence player helped power shares of a top cloud-computing services company higher Monday, while an acquisition in the consumer goods space sent the two stocks on div...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.
NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kenvue Inc. (NYSE: KVUE) and its board of directors concerning the proposed acquisition ...
Kimberly-Clark's $50 billion leap into health and beauty tests investor faith
Kimberly-Clark's nearly $50 billion offer for Tylenol maker Kenvue is a risky bet that the world's biggest consumer market, the United States, will keep growing even as lower-income shoppers trim thei...
KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama
It's been a tough few weeks for the consumer health company Kenvue, after President Trump publicly spread unproven claims about Tylenol, one of its core subsidiary brands. Today, though, it seems like...
Kimberly-Clark Corporation (KMB) M&A Call Transcript
Kimberly-Clark Corporation ( KMB) M&A Call November 3, 2025 8:00 AM EST Company Participants Christopher Jakubik - Investor Relations Contact Michael Hsu - Chairman & CEO Kirk Perry - Interim CEO & D...
Options Corner: Kimberly-Clark's Implosion Offers An Unusual Informational Arbitrage Opportunity
Kimberly-Clark Corporation (NASDAQ:KMB) rattled its shareholders when it earlier announced its acquisition of consumer goods giant Kenvue Inc (NYSE:KVUE). Ordinarily, such an acquisition might make se...
Explainer: Is Tylenol safe to take during pregnancy?
There is no firm evidence of a link between the use of the drug and autism.
Top Stock Movers Now: Amazon, Kenvue, Kimberly-Clark, Beyond Meat, and More
Major U.S. equities indexes were mixed Monday afternoon, as tech stocks gained but most other sectors declined. The S&P 500 and Nasdaq rose, while the Dow fell.
Kenvue deal could double Kimberly-Clark stock's multiple: find out more
Kenvue Inc (NYSE: KVUE) opened about 20% higher this morning after Kimberly-Clark (NYSE: KMB) announced a $40 billion acquisition of the consumer health company. According to its press release, it wil...
Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger
The deal would bring Huggies, Kleenex, Band-Aid, Neutrogena, and Tylenol under one roof, creating a consumer staples giant. Transcript: Caroline Woods: Big brands and big money - Kimberly-Clark is buy...
Kimberly-Clark Is Buying Tylenol Maker Kenvue for Nearly $49B. Here's What You Need to Know
Kenvue (KVUE) shares skyrocketed in early trading Monday after Kleenex and Cottonelle maker Kimberly-Clark (KMB) said it's buying the Tylenol maker in a $48.7 billion deal.
Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal
Kimberly-Clark agreed to buy Kenvue in a deal worth roughly $40 billion in a combination that could create a company with $32 billion in revenue and allow it to surpass Unilever to become the second-b...